News
Press Releases
2015/04/08
Nobel Prize Laureate Professor Barry Sharpless Visits WuXi AppTec Headquarters in Shanghai
SHANGHAI, April 8, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, announced today that Professor Barry Sharpless visited WuXi AppTec's Shanghai headquarters on April 8 and gave an inspiring scientific lecture. Professor Sharpless holds the W. M. Keck professorship in chemistry at The Scripps Research Institute. His visit was part of the 2015 Distinguished Lecture Series, an annual program at WuXi since 2007 that aims to train and inspire WuXi's scientists to pursue scientific excellence.
Read more2015/04/02
WuXiPharmaTechLists Shares of Small-Molecule Manufacturing Subsidiary STA on New Third Board in China
WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, announced today that its wholly owned subsidiary SynTheAll Pharmaceutical Co. Ltd. ("STA") has received approval from the National Equities Exchange and Quotations ("NEEQ") in China to list its shares on the New Third Board, the over-the-counter (OTC) stock exchange in China.
Read more2015/03/12
WuXi PharmaTech To Build New Cell Therapy Manufacturing Facility for CAR T Cells and Other Cancer Immunotherapies
SHANGHAI, March 12, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, announced today that it will soon begin construction of a new, 145,000-square-foot cGMP facility in Philadelphia for the manufacture of cell therapy products. This facility is designed for cell therapy products that contain viral vectors such as chimeric antigen receptor T cell (CAR T cell) therapies. CAR T cells are T cells harvested from a patient's body, engineered to target specific cancers, and then reintroduced into the body.
Read more2015/02/13
WuXi PharmaTech Schedules Fourth-Quarter 2014 Earnings Release
SHANGHAI, Feb. 13, 2015 -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States, today announced that it will release financial results for the fourth quarter of 2014 after the New York Stock Exchange closes on Thursday, March 5, 2015 (which will be Friday morning, March 6, 2015 Shanghai time). The earnings release will be available on the investor relations section of the Company's website at http://www.wuxiapptec.com/.
Read more2015/02/06
WuXiPRA Appoints Two Key Executives
SHANGHAI, February 6, 2015 /PRNewswire/ -- WuXiPRA, a leading clinical services company with operations in the greater China region, today announced appointments of two key executives. Liedong Xu was named Executive Vice President and Chief Operations Officer. He brings 22 years of experience in the pharmaceutical and medical device industries, including roles of increasing responsibility at MSD Allergan, Abbott Santen, and Merck Serono. Jason Wu was appointed Executive Vice President and Chief Medical Officer of WuXiPRA. His 20 years of experience in clinical practice, clinical research, and product development include management positions at Graceway, Auxillium, Sanofi, and Pfizer
Read more